Physician profile
Ornella Addonizio
NPI 1154401149
$8,255.41
in general payments reported to CMS, 2019-2025
22 companies · $1,930 in 2025
The $1,930 reported for 2025 was more than what 89% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,319 · 2020: $965 · 2021: $710 · 2022: $820 · 2023: $1,004 · 2024: $1,508 · 2025: $1,930.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,338 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,337.77 |
| Education | $104.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,369.31 | 2019-2025 | Aristada, Lybalvi |
| Abbvie INC. | $1,298.89 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,174.67 | 2020-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $1,109.82 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $704.16 | 2019-2025 | Rexulti, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $549.56 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Allergan, INC. | $407.89 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $393.60 | 2019-2025 | Invega Sustenna, Spravato |
| Neurocrine Biosciences, INC. | $372.22 | 2019-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $239.55 | 2019-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $156.99 | 2019-2025 | Trintellix |
| Corium, LLC | $90.36 | 2022-2024 | Azstarys |
| Axsome Therapeutics, INC. | $71.42 | 2023-2024 | Auvelity |
| Avanir Pharmaceuticals, INC. | $68.13 | 2019 | |
| Neuronetics, INC. | $65.64 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $51.67 | 2023 | Perseris |
| Lundbeck LLC | $34.76 | 2019 | |
| Eisai INC. | $30.01 | 2020 | |
| Supernus Pharmaceuticals, INC. | $21.53 | 2024 | Qelbree |
| Ironshore Pharmaceuticals INC. | $18.14 | 2019 | |
| Alfasigma USA, INC. | $14.45 | 2020 | |
| Merck Sharp & Dohme LLC | $12.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ornella Addonizio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.